

Eric O Freed

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8781931/eric-o-freed-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

176
papers

10,662
citations

56
h-index

98
g-index

198
ext. papers

11,908
ext. citations

8
avg, IF

6.66
L-index

#	Paper	IF	Citations
176	Expression of Concern: Jiang, H.; Mei, Y.-F. SARS-CoV-2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination In Vitro. 2021, , 2056.. <i>Viruses</i> , 2021 , 14,	6.2	2
175	Rafting through the palms: S-acylation of SARS-CoV-2 spike protein induces lipid reorganization. <i>Developmental Cell</i> , 2021 , 56, 2787-2789	10.2	0
174	A stable immature lattice packages IP for HIV capsid maturation. <i>Science Advances</i> , 2021 , 7,	14.3	9
173	CryoET structures of immature HIV Gag reveal six-helix bundle. <i>Communications Biology</i> , 2021 , 4, 481	6.7	5
172	Mechanism of Viral Glycoprotein Targeting by Membrane-Associated RING-CH Proteins. <i>MBio</i> , 2021 , 12,	7.8	6
171	Maturation of HIV-1. <i>Science</i> , 2021 , 373, 621-622	33.3	0
170	SERINC proteins potentiate antiviral type I IFN production and proinflammatory signaling pathways. <i>Science Signaling</i> , 2021 , 14, eabc7611	8.8	4
169	S-acylation of SARS-CoV-2 spike protein: Mechanistic dissection, in vitro reconstitution and role in viral infectivity. <i>Journal of Biological Chemistry</i> , 2021 , 297, 101112	5.4	8
168	Mechanistic Analysis of the Broad Antiretroviral Resistance Conferred by HIV-1 Envelope Glycoprotein Mutations. <i>MBio</i> , 2021 , 12,	7.8	4
167	Plasma Membrane Anchoring and Gag:Gag Multimerization on Viral RNA Are Critical Properties of HIV-1 Gag Required To Mediate Efficient Genome Packaging. <i>MBio</i> , 2021 , e0325421	7.8	2
166	The viral protein U (Vpu)-interacting host protein ATP6V0C down-regulates cell-surface expression of tetherin and thereby contributes to HIV-1 release. <i>Journal of Biological Chemistry</i> , 2020 , 295, 7327-7340	5.4	3
165	Generation and validation of a highly sensitive bioluminescent HIV-1 reporter vector that simplifies measurement of virus release. <i>Retrovirology</i> , 2020 , 17, 12	3.6	6
164	HIV-1 Envelope Glycoprotein Trafficking and Viral Transmission. <i>Proceedings (mdpi)</i> , 2020 , 50, 17	0.3	
163	PSGL-1 Restricts HIV-1 Infectivity by Blocking Virus Particle Attachment to Target Cells. <i>Proceedings (mdpi)</i> , 2020 , 50, 77	0.3	
162	PSGL-1 restricts HIV-1 infectivity by blocking virus particle attachment to target cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 9537-9545	11.5	21
161	PSGL-1 Inhibits the Incorporation of SARS-CoV and SARS-CoV-2 Spike Glycoproteins into Pseudovirions and Impairs Pseudovirus Attachment and Infectivity. <i>Viruses</i> , 2020 , 13,	6.2	8
160	Structural and Mechanistic Studies of the Rare Myristoylation Signal of the Feline Immunodeficiency Virus. <i>Journal of Molecular Biology</i> , 2020 , 432, 4076-4091	6.5	2

159	HIV-1 Maturation: Lessons Learned from Inhibitors. <i>Viruses</i> , 2020 , 12,	6.2	25
158	Elucidating the Basis for Permissivity of the MT-4 T-Cell Line to Replication of an HIV-1 Mutant Lacking the gp41 Cytoplasmic Tail. <i>Journal of Virology</i> , 2020 , 94,	6.6	2
157	Genomic tagging of endogenous human ESCRT-I complex preserves ESCRT-mediated membrane-remodeling functions. <i>Journal of Biological Chemistry</i> , 2019 , 294, 16266-16281	5.4	9
156	Heavy metal protease takes a tiki torch to HIV assembly. <i>Nature Immunology</i> , 2019 , 20, 668-669	19.1	3
155	Multiple Roles of HIV-1 Capsid during the Virus Replication Cycle. <i>Virologica Sinica</i> , 2019 , 34, 119-134	6.4	46
154	TIM-mediated inhibition of HIV-1 release is antagonized by Nef but potentiated by SERINC proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 5705-5714 ^{11.5} ²⁰	11.5	20
153	Mutations in the HIV-1 envelope glycoprotein can broadly rescue blocks at multiple steps in the virus replication cycle. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 9040-9049	11.5	20
152	Analysis of HIV-1 Matrix-Envelope Cytoplasmic Tail Interactions. <i>Journal of Virology</i> , 2019 , 93,	6.6	15
151	The autophagy protein ATG9A promotes HIV-1 infectivity. <i>Retrovirology</i> , 2019 , 16, 18	3.6	7
150	HIV-1 Matrix Trimerization-Impaired Mutants Are Rescued by Matrix Substitutions That Enhance Envelope Glycoprotein Incorporation. <i>Journal of Virology</i> , 2019 , 94,	6.6	12
149	Authentication Analysis of MT-4 Cells Distributed by the National Institutes of Health AIDS Reagent Program. <i>Journal of Virology</i> , 2019 , 93,	6.6	5
148	Cellular IP Levels Limit HIV Production while Viruses that Cannot Efficiently Package IP Are Attenuated for Infection and Replication. <i>Cell Reports</i> , 2019 , 29, 3983-3996.e4	10.6	31
147	Resistance to Second-Generation HIV-1 Maturation Inhibitors. <i>Journal of Virology</i> , 2019 , 93,	6.6	13
146	Myosin-X is essential to the intercellular spread of HIV-1 Nef through tunneling nanotubes. <i>Journal of Cell Communication and Signaling</i> , 2019 , 13, 209-224	5.2	21
145	HIV-1 packs in PACSIN2 for cell-to-cell spread. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 6885-6887	11.5	2
144	Single molecule fate of HIV-1 envelope reveals late-stage viral lattice incorporation. <i>Nature Communications</i> , 2018 , 9, 1861	17.4	22
143	High-Mannose But Not Complex-Type Glycosylation of Tetherin Is Required for Restriction of HIV-1 Release. <i>Viruses</i> , 2018 , 10,	6.2	7
142	Identification of a Structural Element in HIV-1 Gag Required for Virus Particle Assembly and Maturation. <i>MBio</i> , 2018 , 9,	7.8	8

141	The Role of Lipids in Retroviral Replication 2018 , 353-399		1
140	"Expand and Click": A New Method for Labeling HIV-1 Envelope Glycoproteins. <i>Cell Chemical Biology</i> , 2017 , 24, 548-550	8.2	3
139	Quenching protein dynamics interferes with HIV capsid maturation. <i>Nature Communications</i> , 2017 , 8, 1779	17.4	42
138	Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 190-7	5.9	34
137	Getting IN on Viral RNA Condensation and Virion Maturation. <i>Cell</i> , 2016 , 166, 1082-1083	56.2	1
136	A Triazinone Derivative Inhibits HIV-1 Replication by Interfering with Reverse Transcriptase Activity. <i>ChemMedChem</i> , 2016 , 11, 2320-2326	3.7	3
135	Identification of potent maturation inhibitors against HIV-1 clade C. <i>Scientific Reports</i> , 2016 , 6, 27403	4.9	12
134	Identification of an HIV-1 Mutation in Spacer Peptide 1 That Stabilizes the Immature CA-SP1 Lattice. <i>Journal of Virology</i> , 2016 , 90, 972-8	6.6	21
133	Structural and Molecular Determinants of Membrane Binding by the HIV-1 Matrix Protein. <i>Journal of Molecular Biology</i> , 2016 , 428, 1637-55	6.5	55
132	The Use of Minimal RNA Toeholds to Trigger the Activation of Multiple Functionalities. <i>Nano Letters</i> , 2016 , 16, 1746-53	11.5	31
131	Biochemical evidence of a role for matrix trimerization in HIV-1 envelope glycoprotein incorporation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E182-90	11.5	41
130	Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain. <i>Journal of Virology</i> , 2016 , 90, 768-79	6.6	18
129	The Vpu-interacting Protein SGTA Regulates Expression of a Non-glycosylated Tetherin Species. <i>Scientific Reports</i> , 2016 , 6, 24934	4.9	6
128	Trimer Enhancement Mutation Effects on HIV-1 Matrix Protein Binding Activities. <i>Journal of Virology</i> , 2016 , 90, 5657-5664	6.6	16
127	HIV-1 gag: an emerging target for antiretroviral therapy. <i>Current Topics in Microbiology and Immunology</i> , 2015 , 389, 171-201	3.3	18
126	HIV-1 assembly, release and maturation. <i>Nature Reviews Microbiology</i> , 2015 , 13, 484-96	22.2	303
125	NMR structure of the myristylated feline immunodeficiency virus matrix protein. <i>Viruses</i> , 2015 , 7, 2210-29	29.2	17
124	Rab27a controls HIV-1 assembly by regulating plasma membrane levels of phosphatidylinositol 4,5-bisphosphate. <i>Journal of Cell Biology</i> , 2015 , 209, 435-52	7.3	41

123	IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein. <i>Cell Reports</i> , 2015 , 13, 145-156	10.6	109
122	The cytoplasmic tail of retroviral envelope glycoproteins. <i>Progress in Molecular Biology and Translational Science</i> , 2015 , 129, 253-84	4	16
121	Elucidating the mechanism by which compensatory mutations rescue an HIV-1 matrix mutant defective for gag membrane targeting and envelope glycoprotein incorporation. <i>Journal of Molecular Biology</i> , 2015 , 427, 1413-1427	6.5	17
120	TIM-family proteins inhibit HIV-1 release. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, E3699-707	11.5	57
119	MicroRNA binding to the HIV-1 Gag protein inhibits Gag assembly and virus production. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, E2676-83	11.5	49
118	Multifunctional RNA nanoparticles. <i>Nano Letters</i> , 2014 , 14, 5662-71	11.5	136
117	Mutations in the feline immunodeficiency virus envelope glycoprotein confer resistance to a dominant-negative fragment of Tsg101 by enhancing infectivity and cell-to-cell virus transmission. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2014 , 1838, 1143-52	3.8	5
116	Distribution of ESCRT machinery at HIV assembly sites reveals virus scaffolding of ESCRT subunits. <i>Science</i> , 2014 , 343, 653-6	33.3	141
115	The role of matrix in HIV-1 envelope glycoprotein incorporation. <i>Trends in Microbiology</i> , 2014 , 22, 372-8	12.4	42
114	In COS cells Vpu can both stabilize tetherin expression and counteract its antiviral activity. <i>PLoS ONE</i> , 2014 , 9, e111628	3.7	7
113	HIV-1 Vpu accessory protein induces caspase-mediated cleavage of IRF3 transcription factor. <i>Journal of Biological Chemistry</i> , 2014 , 289, 35102-10	5.4	21
112	Activation of virus uptake through induction of macropinocytosis with a novel polymerizing peptide. <i>FASEB Journal</i> , 2014 , 28, 106-16	0.9	1
111	Dual-acting stapled peptides target both HIV-1 entry and assembly. <i>Retrovirology</i> , 2013 , 10, 136	3.6	30
110	Global rescue of defects in HIV-1 envelope glycoprotein incorporation: implications for matrix structure. <i>PLoS Pathogens</i> , 2013 , 9, e1003739	7.6	54
109	Structure-based in silico identification of ubiquitin-binding domains provides insights into the ALIX-V:ubiquitin complex and retrovirus budding. <i>EMBO Journal</i> , 2013 , 32, 538-51	13	50
108	Reevaluation of the requirement for TIP47 in human immunodeficiency virus type 1 envelope glycoprotein incorporation. <i>Journal of Virology</i> , 2013 , 87, 3561-70	6.6	22
107	A two-pronged structural analysis of retroviral maturation indicates that core formation proceeds by a disassembly-reassembly pathway rather than a displacive transition. <i>Journal of Virology</i> , 2013 , 87, 13655-64	6.6	53
106	HIV type 1 Gag as a target for antiviral therapy. <i>AIDS Research and Human Retroviruses</i> , 2012 , 28, 54-75	1.6	61

105	ARRDC1 as a mediator of microvesicle budding. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 4025-6	11.5	24
104	Structural and functional insights into the HIV-1 maturation inhibitor binding pocket. <i>PLoS Pathogens</i> , 2012 , 8, e1002997	7.6	44
103	Viral latency and potential eradication of HIV-1. <i>Expert Review of Anti-Infective Therapy</i> , 2012 , 10, 855-7	5.5	5
102	HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. <i>Journal of Molecular Biology</i> , 2011 , 410, 582-608	6.5	290
101	New insights into HIV assembly and trafficking. <i>Physiology</i> , 2011 , 26, 236-51	9.8	65
100	Targeting the HIV entry, assembly and release pathways for anti-HIV gene therapy. <i>Virology</i> , 2011 , 415, 95-106	3.6	6
99	The interdomain linker region of HIV-1 capsid protein is a critical determinant of proper core assembly and stability. <i>Virology</i> , 2011 , 421, 253-65	3.6	41
98	Antiviral activity of Helical stapled peptides designed from the HIV-1 capsid dimerization domain. <i>Retrovirology</i> , 2011 , 8, 28	3.6	49
97	Elucidation of New Binding Interactions with the Tumor Susceptibility Gene 101 (Tsg101) Protein Using Modified HIV-1 Gag-p6 Derived Peptide Ligands. <i>ACS Medicinal Chemistry Letters</i> , 2011 , 2, 337-341	4.3	8
96	Evidence of a role for soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) machinery in HIV-1 assembly and release. <i>Journal of Biological Chemistry</i> , 2011 , 286, 29861-71	5.4	24
95	A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 3324-9	5.9	32
94	HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice. <i>Journal of Virology</i> , 2011 , 85, 1420-8	6.6	85
93	Effect of mutations in the human immunodeficiency virus type 1 protease on cleavage of the gp41 cytoplasmic tail. <i>Journal of Virology</i> , 2010 , 84, 3121-6	6.6	14
92	The Role of Lipids in Retrovirus Replication. <i>Viruses</i> , 2010 , 2, 1146-1180	6.2	75
91	Macrophages and Cell-Cell Spread of HIV-1. <i>Viruses</i> , 2010 , 2, 1603-1620	6.2	34
90	Myristate exposure in the human immunodeficiency virus type 1 matrix protein is modulated by pH. <i>Biochemistry</i> , 2010 , 49, 9551-62	3.2	35
89	FIV Gag: virus assembly and host-cell interactions. <i>Veterinary Immunology and Immunopathology</i> , 2010 , 134, 3-13	2	21
88	EMBO World Lecture Course Virus/Host: Partners in Pathogenesis. <i>Future Virology</i> , 2010 , 5, 379-383	2.4	

87	Crystallographic and functional analysis of the ESCRT-I /HIV-1 Gag PTAP interaction. <i>Structure</i> , 2010 , 18, 1536-47	5.2	50
86	Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat. <i>Retrovirology</i> , 2010 , 7, 36	3.6	65
85	Novel approaches to inhibiting HIV-1 replication. <i>Antiviral Research</i> , 2010 , 85, 119-41	10.8	107
84	The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation. <i>Virology</i> , 2010 , 400, 137-44	3.6	49
83	Application of ring-closing metathesis macrocyclization to the development of Tsg101-binding antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010 , 20, 318-21	2.9	10
82	Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457). <i>Journal of Virology</i> , 2009 , 83, 4884-94	6.6	43
81	Virus maturation as a new HIV-1 therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2009 , 13, 895-908	6.4	50
80	Ion-abrasion scanning electron microscopy reveals surface-connected tubular conduits in HIV-infected macrophages. <i>PLoS Pathogens</i> , 2009 , 5, e1000591	7.6	128
79	Evidence that productive human immunodeficiency virus type 1 assembly can occur in an intracellular compartment. <i>Journal of Virology</i> , 2009 , 83, 5375-87	6.6	64
78	Functional role of Alix in HIV-1 replication. <i>Virology</i> , 2009 , 391, 284-92	3.6	69
77	Defects in cellular sorting and retroviral assembly induced by GGA overexpression. <i>BMC Cell Biology</i> , 2009 , 10, 72		12
76	Lipids and membrane microdomains in HIV-1 replication. <i>Virus Research</i> , 2009 , 143, 162-76	6.4	131
75	Welcome to viruses: a new open-access, multidisciplinary forum for virology. <i>Viruses</i> , 2009 , 1, 1-2	6.2	1
74	Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2009 , 9, 70-4		15
73	Methods for the study of HIV-1 assembly. <i>Methods in Molecular Biology</i> , 2009 , 485, 163-84	1.4	24
72	Recent progress in antiretrovirals--lessons from resistance. <i>Drug Discovery Today</i> , 2008 , 13, 424-32	8.8	35
71	A cell-penetrating helical peptide as a potential HIV-1 inhibitor. <i>Journal of Molecular Biology</i> , 2008 , 378, 565-80	6.5	175
70	Structure of the myristylated human immunodeficiency virus type 2 matrix protein and the role of phosphatidylinositol-(4,5)-bisphosphate in membrane targeting. <i>Journal of Molecular Biology</i> , 2008 , 382, 434-47	6.5	80

69	GGA and Arf proteins modulate retrovirus assembly and release. <i>Molecular Cell</i> , 2008 , 30, 227-38	17.6	50
68	Photoinduced reactivity of the HIV-1 envelope glycoprotein with a membrane-embedded probe reveals insertion of portions of the HIV-1 Gp41 cytoplasmic tail into the viral membrane. <i>Biochemistry</i> , 2008 , 47, 1977-83	3.2	30
67	Inhibition of human immunodeficiency virus type 1 assembly and release by the cholesterol-binding compound amphotericin B methyl ester: evidence for Vpu dependence. <i>Journal of Virology</i> , 2008 , 82, 9776-81	6.6	40
66	Real-time visualization of HIV-1 GAG trafficking in infected macrophages. <i>PLoS Pathogens</i> , 2008 , 4, e1000015	9.15	161
65	Molecular characterization of feline immunodeficiency virus budding. <i>Journal of Virology</i> , 2008 , 82, 21066-69	6.19	39
64	SAR by oxime-containing peptide libraries: application to Tsg101 ligand optimization. <i>ChemBioChem</i> , 2008 , 9, 2000-4	3.8	25
63	Functional replacement of a retroviral late domain by ubiquitin fusion. <i>Traffic</i> , 2008 , 9, 1972-83	5.7	54
62	Human immunodeficiency virus type 1 assembly, release, and maturation. <i>Advances in Pharmacology</i> , 2007 , 55, 347-87	5.7	125
61	Beyond Tsg101: the role of Alix in 'ESCRTing' HIV-1. <i>Nature Reviews Microbiology</i> , 2007 , 5, 912-6	22.2	130
60	Structural basis for viral late-domain binding to Alix. <i>Nature Structural and Molecular Biology</i> , 2007 , 14, 194-9	17.6	126
59	A second-site suppressor significantly improves the defective phenotype imposed by mutation of an aromatic residue in the N-terminal domain of the HIV-1 capsid protein. <i>Virology</i> , 2007 , 359, 105-15	3.6	7
58	Depletion of cellular cholesterol inhibits membrane binding and higher-order multimerization of human immunodeficiency virus type 1 Gag. <i>Virology</i> , 2007 , 360, 27-35	3.6	76
57	HIV-1 escape from the entry-inhibiting effects of a cholesterol-binding compound via cleavage of gp41 by the viral protease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 8467-71	11.5	40
56	Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV-1-mediated bystander apoptosis and fusion/hemifusion. <i>Journal of Biological Chemistry</i> , 2007 , 282, 16899-906	5.4	35
55	An Alix fragment potently inhibits HIV-1 budding: characterization of binding to retroviral YPXL late domains. <i>Journal of Biological Chemistry</i> , 2007 , 282, 3847-55	5.4	82
54	HIV-1 Gag trafficking. <i>Future HIV Therapy</i> , 2007 , 1, 427-438		11
53	Influenza virus not cRAFTy enough to dodge viperin. <i>Cell Host and Microbe</i> , 2007 , 2, 71-2	23.4	11
52	Point mutations in the HIV-1 matrix protein turn off the myristyl switch. <i>Journal of Molecular Biology</i> , 2007 , 366, 574-85	6.5	94

51	Determinants of activity of the HIV-1 maturation inhibitor PA-457. <i>Virology</i> , 2006 , 356, 217-24	3.6	56
50	Mutation of dileucine-like motifs in the human immunodeficiency virus type 1 capsid disrupts virus assembly, gag-gag interactions, gag-membrane binding, and virion maturation. <i>Journal of Virology</i> , 2006 , 80, 7939-51	6.6	52
49	In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). <i>Journal of Virology</i> , 2006 , 80, 10957-71	6.6	98
48	A mutation in the human immunodeficiency virus type 1 Gag protein destabilizes the interaction of the envelope protein subunits gp120 and gp41. <i>Journal of Virology</i> , 2006 , 80, 2405-17	6.6	55
47	Inhibition of HIV-1 replication by amphotericin B methyl ester: selection for resistant variants. <i>Journal of Biological Chemistry</i> , 2006 , 281, 28699-711	5.4	49
46	HIV-1 Gag: flipped out for PI(4,5)P(2). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 11101-2	11.5	33
45	Effects of Gag mutation and processing on retroviral dimeric RNA maturation. <i>Journal of Virology</i> , 2006 , 80, 1242-9	6.6	22
44	The cell biology of HIV-1 and other retroviruses. <i>Retrovirology</i> , 2006 , 3, 77	3.6	37
43	Complex I polymorphisms, bigenomic heterogeneity, and family history in Virginians with Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2006 , 247, 224-30	3.2	20
42	Hydrazone- and hydrazide-containing N-substituted glycines as peptoid surrogates for expedited library synthesis: application to the preparation of Tsg101-directed HIV-1 budding antagonists. <i>Organic Letters</i> , 2006 , 8, 5165-8	6.2	42
41	Role of lipid rafts in virus replication. <i>Advances in Virus Research</i> , 2005 , 64, 311-58	10.7	117
40	Pravastatin does not have a consistent antiviral effect in chronically HIV-infected individuals on antiretroviral therapy. <i>Aids</i> , 2005 , 19, 1109-11	3.5	23
39	Association of human immunodeficiency virus type 1 gag with membrane does not require highly basic sequences in the nucleocapsid: use of a novel Gag multimerization assay. <i>Journal of Virology</i> , 2005 , 79, 14131-40	6.6	77
38	Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body. <i>Journal of Virology</i> , 2004 , 78, 1552-63	6.6	223
37	Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity. <i>Journal of Virology</i> , 2004 , 78, 1026-31	6.6	133
36	Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. <i>Journal of Biological Chemistry</i> , 2004 , 279, 35822-8	5.4	221
35	Late domain-dependent inhibition of equine infectious anemia virus budding. <i>Journal of Virology</i> , 2004 , 78, 724-32	6.6	61
34	Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 14889-94	11.5	388

33	Mechanisms of enveloped virus release. <i>Virus Research</i> , 2004 , 106, 85-6	6.4	14
32	Retrovirus budding. <i>Virus Research</i> , 2004 , 106, 87-102	6.4	252
31	HIV-1 and the host cell: an intimate association. <i>Trends in Microbiology</i> , 2004 , 12, 170-7	12.4	77
30	The HIV-TSG101 interface: recent advances in a budding field. <i>Trends in Microbiology</i> , 2003 , 11, 56-9	12.4	60
29	Defects in human immunodeficiency virus budding and endosomal sorting induced by TSG101 overexpression. <i>Journal of Virology</i> , 2003 , 77, 6507-19	6.6	91
28	Human immunodeficiency virus type 1 N-terminal capsid mutants containing cores with abnormally high levels of capsid protein and virtually no reverse transcriptase. <i>Journal of Virology</i> , 2003 , 77, 12592-602	6.6	46
27	Mechanisms of HIV type 1-induced cognitive impairment: evidence for hippocampal cholinergic involvement with overstimulation of the VIPergic system by the viral coat protein core. <i>AIDS Research and Human Retroviruses</i> , 2002 , 18, 1189-95	1.6	13
26	The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner. <i>Journal of Virology</i> , 2002 , 76, 105-17	6.6	175
25	Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 955-60	11.5	299
24	Viral late domains. <i>Journal of Virology</i> , 2002 , 76, 4679-87	6.6	372
23	Virology. Rafting with Ebola. <i>Science</i> , 2002 , 296, 279	33.3	36
22	HIV-1 replication. <i>Somatic Cell and Molecular Genetics</i> , 2001 , 26, 13-33		135
21	Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells. <i>Journal of Virology</i> , 2001 , 75, 9357-66	6.6	122
20	Transport of human immunodeficiency virus type 1 pseudoviruses across the blood-brain barrier: role of envelope proteins and adsorptive endocytosis. <i>Journal of Virology</i> , 2001 , 75, 4681-91	6.6	101
19	Wild-type and YMDD mutant murine leukemia virus reverse transcriptases are resistant to 2',3'-dideoxy-3'-thiacytidine. <i>Journal of Virology</i> , 2000 , 74, 6669-74	6.6	17
18	Role of the Gag matrix domain in targeting human immunodeficiency virus type 1 assembly. <i>Journal of Virology</i> , 2000 , 74, 2855-66	6.6	198
17	Relationship between human immunodeficiency virus type 1 Gag multimerization and membrane binding. <i>Journal of Virology</i> , 2000 , 74, 5142-50	6.6	101
16	Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail. <i>Journal of Virology</i> , 2000 , 74, 3548-54	6.6	181

15	Relationship between Human Immunodeficiency Virus Type 1 Gag Multimerization and Membrane Binding. <i>Journal of Virology</i> , 2000 , 74, 5142-5150	6.6	2
14	Cellular motor protein KIF-4 associates with retroviral Gag. <i>Journal of Virology</i> , 1999 , 73, 10508-13	6.6	85
13	Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus. <i>Journal of Virology</i> , 1999 , 73, 4136-44	6.6	206
12	Reversion of a human immunodeficiency virus type 1 matrix mutation affecting Gag membrane binding, endogenous reverse transcriptase activity, and virus infectivity. <i>Journal of Virology</i> , 1999 , 73, 4728-37	6.6	24
11	HIV-1 gag proteins: diverse functions in the virus life cycle. <i>Virology</i> , 1998 , 251, 1-15	3.6	557
10	Cleavage of the murine leukemia virus transmembrane env protein by human immunodeficiency virus type 1 protease: transdominant inhibition by matrix mutations. <i>Journal of Virology</i> , 1998 , 72, 9621-7	6.6	29
9	Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle. <i>Journal of Virology</i> , 1998 , 72, 4116-26	6.6	112
8	Phosphorylation of residue 131 of HIV-1 matrix is not required for macrophage infection. <i>Cell</i> , 1997 , 88, 171-3; discussion 173-4	56.2	61
7	The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. <i>Journal of Biological Chemistry</i> , 1995 , 270, 23883-6	5.4	216
6	HIV-1 infection of non-dividing cells. <i>Nature</i> , 1994 , 369, 107-8	50.4	90
5	Cells induced to express a human immunodeficiency virus type 1 envelope gene mutant inhibit the spread of wild-type virus. <i>Human Gene Therapy</i> , 1992 , 3, 391-7	4.8	33
4	Studies on the role of the V3 loop in human immunodeficiency virus type 1 envelope glycoprotein function. <i>AIDS Research and Human Retroviruses</i> , 1992 , 8, 1611-8	1.6	14
3	Analysis of HIV-1 envelope mutants and pseudotyping of replication-defective HIV-1 vectors by genetic complementation. <i>AIDS Research and Human Retroviruses</i> , 1992 , 8, 1669-77	1.6	19
2	Identification of conserved residues in the human immunodeficiency virus type 1 principal neutralizing determinant that are involved in fusion. <i>AIDS Research and Human Retroviruses</i> , 1991 , 7, 807-11	1.6	29
1	CryoET structures of immature HIV Gag reveal a complete six-helix bundle and stabilizing small molecules distinct from IP6		1